Effect of Stevioside in Postpandrial Glucose in Healthy Adults

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2011 by Basque Health Service.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by (Responsible Party):
Antxon Apiñaniz Fernández de LArrinoa, Basque Health Service
ClinicalTrials.gov Identifier:
NCT01488383
First received: December 7, 2011
Last updated: February 6, 2013
Last verified: December 2011
  Purpose

A natural sweetener (Stevia Rebaudina Bertoni) reduces blood glucose levels and blood pressure according to various preclinical and clinical studies conducted worldwide. Since it is not found many studies in the literature wich compares Stevia Rebaudiana with saccharin, we've proposed a randomized crossover clinical trial comparing the effects on postprandial capillary blood glucose and blood pressure in healthy adults.

Sample: healthy professionals from two health centers in Alava (Kakuabizkarra primary care center and Txagorritxu hospital). Inclusion criteria: Professionals of two health centers of Álava (Lakuabizkarra and Txagorritxu) and active employment status at the beginning of the trial, weighing more than 50kg and age over 18 years.

Intervention: 200mg capsules of Stevia or 250mgcapsules of saccharin. Measurements: Capillary blood glucose and blood pressure, fasting and after eating. Evaluation of satiety, hunger and fullness by questionnaire after intake, and at the end of the day.

Statistical analysis: Compare the postprandial capillary glucose levels between 8 am and 1 st hour, 2nd hour 3rd hour after intake between treatments by ANCOVA. We will also compare blood pressure before and after intake between treatments. We will also compare by t test or paired Wilcoxom (depending on the nature of the variable) the results of the questionnaire after intake between treatments.


Condition Intervention
Hyperglycemia
Hypertension
Drug: Purified extract of Rebaudina Stevia-Stevioside
Drug: Sodium saccharin

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Comparison of the Effect on Postpandrial Capillary Blood Glucose Between Oral Stevioside Versus Saccharin in Healthy Adults.

Resource links provided by NLM:


Further study details as provided by Basque Health Service:

Primary Outcome Measures:
  • change in capillary blood glucose levels [ Time Frame: at baseline and and at first hour after intake ] [ Designated as safety issue: No ]
    Change in capillary blood glucose levels after treatment


Secondary Outcome Measures:
  • change in blood pressure [ Time Frame: at baseline and and at third hour after intake ] [ Designated as safety issue: No ]
    Change in blodd pressure after treatment

  • feeling of fullness, hunger and satiety after intake [ Time Frame: At baseline and and at third hour after intake ] [ Designated as safety issue: No ]
    feeling of fullness, hunger and satiety after treatment

  • Adverse reactions of treatments (nausea, diarrhea, vomiting, allergic signs) [ Time Frame: After intake ] [ Designated as safety issue: Yes ]
    To describe and compare the adverse reactions of each treatment nausea, diarrhea, vomiting, allergic signs.


Estimated Enrollment: 120
Study Start Date: September 2013
Estimated Study Completion Date: September 2013
Estimated Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Stevioside capsules 200mg
Capsules of 200mg Stevioside
Drug: Purified extract of Rebaudina Stevia-Stevioside
volunteers will take only one capsule of stevioside (one day), and then corresponding measurements will be performed.
Other Name: Gycostevia-95
Active Comparator: Sodium Saccharin 250 capsules
Capsules of 250mg Saccharin
Drug: Sodium saccharin
Volunteers will take one capsule of saccharin 250mg (one day) and then, corresponding measurements will be performed
Other Name: Saccharin

  Hide Detailed Description

Detailed Description:

State of the art: Excessive intake of calories and sugar diets cause weight gain and impaired glucose tolerance in healthy subjects (1). These diets raise postpandrial blood glucose and insulin levels and cause metabolic and hormonal changes that induce feelings of hunger and fat deposition. These diets are also associated with diseases such as diabetes, cardiovascular disease and cancer (2).

The origin of the artificial sweeteners dates back to 1879 with the accidental discovery of saccharin. France in 1902 and the United States in 1912 officially banned its use because of their lack of nutritional value. But Europe allowed the use of saccharin during sugar rationing in the world wars (3). In the past three decades has increased the consumption of these sweeteners as it has allowed many people suffering from obesity and / or diabetes restore some degree of palatability to foods (4).

Stevia rebaudiana Bertoni (Bertoni), common name "sweet herb of Paraguay" is a plant native to Paraguay and Brazil, known by Indians as Ka'a-he'e (sweet grass). Its leaves were used since pre-Columbian times for medicinal purposes and as a sweetener because of its sweet taste (5). Japan and Brazil have more than 20 years using it as a natural sweetener. The main sweet component of Stevia is the Stevioside, a glycoside 300 times sweeter than sucrose (7).

The benefits of stevia as a dietary supplement in humans are many: it is stable, non-caloric and offers a good dental health. In addition, no significant adverse effects have occurred from their use (6).

There have been several studies that compare the decline in blood glucose and insulin levels of Stevia versus many sweeteners. It has been administered to healthy and diabetic rats (8), healthy humans (9,10), obese (10) and diabetic (11).

Another therapeutic properties of Stevia rebaudiana is a reduction in blood pressure, systolic and diastolic as Chan et al demonstrated in a randomized clinical trial conducted in China (12,13).

Toxicity studies in animals (14) and pregnant (15) have concluded that consumption of Stevia is safe at commonly used doses of sweetener (7). Furthermore, the quality of life did not deteriorate (12) nor adverse effects have been detected (16).

The available data suggest that stevia has immunostimulatory activity and inflammation modulating. But these effects have not been demonstrated in a robust in animal models or cell lines. If confirmed, the used of stevia could cause problems in some subgroups of population like in people with autoimmune diseases or gastrointestinal tract inflammation (6).

In USA it is used as a dietary supplement since 1995, but was evaluated as a sweetener by the European Scientific Committee on Food for 1984, 1989 and 1999 and concluded that it was not toxicologically acceptable because there were not enough studies (6). However, recently, the FDA, WHO and FAO have approved Stevia as a "food additive" for use in people of all ages (17).

In summary, the literature indicates that steviol can be used safely as a sweetener in the healthy population, and brings significant benefits for controlling blood glucose levels and blood pressure. However, to date there are few studies comparing Stevia with other common sweeteners. For this reason, and to compare the effect of saccharin versus Stevioside, we plan to conduct this randomized crossover clinical trial.

Study justification: Diets high in sucrose promote weight gain, causing alterations in glucose tolerance in healthy subjects (1) and are associated with metabolic disorders like diabetes wich is characterized by plasma glucose levels above the normal limits and if it isn't adequately treated can lead to complications such as neuropathy, retinopathy, neuropathy, diabetic microangiopathy and atherosclerosis.

Since diabetic patients should not eat sugar, artificial sweetener use has increased over the past three decades due to the fact that consumption of these substances has allowed many people suffering from obesity and /or diabetes to restore some degree of palatability to food (4). Among them, a natural sweetener, Stevioside also reduces the levels of postprandial glucose and insulin, and blood pressure. Besides the consumption of Stevia is safe at doses normally used as a sweetener

According to the reviewed literature, Stevioside can be used safely as a sweetener in the healthy population, providing significant benefits for controlling blood glucose levels and blood pressure with no serious adverse reactions. In the most of studies from literature, Stevioside's effect is compared with placebo, however, to date few studies have been conducted wich compare it with other sweeteners commonly used by people. For this reason, and to compare the effect and safety of Stevioside versus Saccharin we have planed this randomized crossover clinical trial.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Professionals of sanitary centers in active working situation at start date of clinical trial.
  • Weight over 50kg.
  • Age over 18 years.

Exclusion Criteria:

  • History of diabetes mellitus, arterial hypertension or hypercholesterolemia.
  • Obesity (BMI ≥ 30kg/m2)
  • Cardiovascular disease.
  • Enrollment in other clinical trial with medicaments within three months.
  • Any endocrine disease other than diabetes.
  • Glucocorticoids treatment.
  • Pregnant women.
  • Herball allergy.
  • Autoimmune diseases.
  • Inflammatory bowel disease.
  • Allergy to sulfonamides.
  • Steven-Johnson syndrome.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01488383

Contacts
Contact: Antxon Apiñaniz 945006800 antxon.apinanizfernandez@osakidetza.net

Locations
Spain
Basque Public Health Service-Osakidetza (Lakuabizkarra primary care center and Txagorritxu hospital) Not yet recruiting
Vitoria-Gasteiz, Alava, Spain, 01009
Contact: Antxon Apiñaniz    945006800    antxon.apinanizfernandez@osakidetza.net   
Principal Investigator: Antxon Apiñaniz         
Sub-Investigator: Lucía Garate         
Sub-Investigator: Raquel Cobos         
Sub-Investigator: Erika Miranda         
Sponsors and Collaborators
Basque Health Service
  More Information

No publications provided

Responsible Party: Antxon Apiñaniz Fernández de LArrinoa, Primary health care physician, Basque Health Service
ClinicalTrials.gov Identifier: NCT01488383     History of Changes
Other Study ID Numbers: ST-01
Study First Received: December 7, 2011
Last Updated: February 6, 2013
Health Authority: Spain: Ethics Committee

Keywords provided by Basque Health Service:
Hyperglycemia
Diabetes
Blood glucose
Hypertension
Anti hypertensive agents
Anti hypertensive drugs
Anti hypertensive

Additional relevant MeSH terms:
Hyperglycemia
Hypertension
Glucose Metabolism Disorders
Metabolic Diseases
Vascular Diseases
Cardiovascular Diseases
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 22, 2014